About Century Therapeutics, Inc.
https://www.centurytx.comCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
CEO
Brent Pfeiffenberger
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Piper Sandler
Overweight
Leerink Partners
Market Perform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BOXER CAPITAL, LLC
Shares:3.9M
Value:$7.88M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.54M
Value:$7.15M
BLACKROCK INC.
Shares:2.9M
Value:$5.85M
Summary
Showing Top 3 of 63
About Century Therapeutics, Inc.
https://www.centurytx.comCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $25.99M ▼ | $-34.42M ▼ | 0% | $-0.4 ▼ | $-31.29M ▼ |
| Q2-2025 | $0 ▼ | $31.08M ▼ | $-32.54M ▼ | 0% ▼ | $-0.38 ▼ | $-29.34M ▼ |
| Q1-2025 | $109.16M ▲ | $34.99M ▼ | $76.56M ▲ | 70.13% ▲ | $0.89 ▲ | $77.4M ▲ |
| Q4-2024 | $4.17M ▲ | $41.46M ▲ | $-36.07M ▼ | -864.44% ▲ | $-0.46 ▼ | $-30.98M ▼ |
| Q3-2024 | $791K | $35.58M | $-31.23M | -3.95K% | $-0.37 | $-27.94M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $132.75M ▼ | $244.72M ▼ | $68.37M ▼ | $176.35M ▼ |
| Q2-2025 | $155.84M ▼ | $284.69M ▼ | $74.79M ▼ | $209.9M ▼ |
| Q1-2025 | $165.12M ▼ | $315.61M ▼ | $75.17M ▼ | $240.44M ▲ |
| Q4-2024 | $189.29M ▼ | $353.22M ▼ | $191.85M ▼ | $161.36M ▼ |
| Q3-2024 | $198.11M | $388.62M | $192.93M | $195.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.43M ▼ | $-25.58M ▲ | $24.67M ▼ | $0 | $-913K ▼ | $-25.78M ▲ |
| Q2-2025 | $-32.54M ▼ | $-27.59M ▲ | $32.54M ▲ | $0 ▼ | $4.95M ▲ | $-27.91M ▲ |
| Q1-2025 | $76.56M ▲ | $-34.62M ▼ | $27.93M ▼ | $120K ▲ | $-6.57M ▼ | $-34.62M ▼ |
| Q4-2024 | $-36.07M ▼ | $-24.22M ▲ | $30.61M ▼ | $-602K ▼ | $5.78M ▼ | $-24.38M ▲ |
| Q3-2024 | $-31.23M | $-28.33M | $39.2M | $273K | $11.14M | $-27.53M |
CEO
Brent Pfeiffenberger
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Piper Sandler
Overweight
Leerink Partners
Market Perform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BOXER CAPITAL, LLC
Shares:3.9M
Value:$7.88M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.54M
Value:$7.15M
BLACKROCK INC.
Shares:2.9M
Value:$5.85M
Summary
Showing Top 3 of 63